Riskpilot← Back to searchSign inGet full accessLabquality Oy
OYActiveY-tunnus 0110079-1Kumpulantie 15Technical testing and analysis · NACE 7120Est. 1972— employees
Revenue 2024
EUR 12,8M
-1277367500% vs 2023
EBITDA margin
-3.1%
-3622582% vs 2023
Equity ratio
83.3%
Financial strength
Net profit 2024
EUR -1,2M
| Revenue | EUR 12,8M | -1277367500% |
| EBITDA | EUR -398K | -3622582% |
| Net profit | EUR -1,2M | — |
| Total assets | EUR 23,1M | +84% |
| Equity | EUR 19,3M | +96% |
| Employees | — | — |
Legal name
Labquality Oy
Y-tunnus number
0110079-1
Legal form
Osakeyhtiö
NACE code
7120 · Technical testing and analysis
Founded
14. tammikuuta 1972
Share capital
EUR 0
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsenet ja toimitusjohtaja kukin yksin
Company purpose
Yhtiön toimialana on sosiaali- ja terveydenhuollon, ympäristöterveydenhuollon ja teollisuuden analyysitoiminnan, sertifioinnin ja laadun edistäminen mm. ulkoisten laadunarviointipalvelujen ja vertailumittauskierrosten kautta. Lisäksi yhtiön toimintaan kuuluu alaan kuuluva viestintä ja koulutus sekä konsultointi. Yrityksen toimintaan kuuluvat myös sosiaali- ja terveydenhuollon toimijoiden sertifiointi- ja laadunarviointitoiminta. Lisäksi yhtiön toimialaan kuuluu lääkinnällisten laitteiden parissa toimivien yritysten palvelu liittyen laitteiden rekisteröintiin, viranomaishyväksyntään, tutkimukseen, kehitykseen ja valmistukseen sekä palvelu liittyen yritysten laatujärjestelmien kehittämiseen ja ylläpitoon, sekä muu laillinen liiketoiminta. Yhtiö toimii sekä kotimaassa että kansainvälisesti. Lisäksi Yhtiö voi omistaa kiinteistöjä ja huoneistoja sekä harjoittaa arvopaperikauppaa.
Address
Kumpulantie 15
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 8 160 | 10 702 | 11 451 | −0 | 12 774 |
| Staff expenses | −3 197 | −4 120 | −4 984 | 0 | −5 462 |
| EBITDA | 1 524 | 2 667 | 1 780 | −0 | −398 |
| Depreciation & amort. | −486 | −487 | −532 | −0 | −610 |
| EBIT | 1 039 | 2 180 | 1 249 | −0 | −1 008 |
| Net financials | −4 | −2 | −8 | 0 | −82 |
| Profit before tax | 1 035 | 2 177 | 1 241 | −0 | −1 197 |
| Tax | 213 | 455 | 242 | −0 | 0 |
| Net profit | 822 | 1 722 | 999 | 0 | −1 197 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 6 810 | 7 800 | 8 560 | 12 582 | 23 114 |
| Equity | 5 134 | 5 856 | 6 354 | 9 835 | 19 256 |
| Long-term debt | — | 113 | 244 | 39 | 0 |
| Short-term debt | 1 676 | 1 831 | 1 963 | 2 615 | 3 858 |
| Total debt | 1 676 | 1 945 | 2 206 | 2 746 | 3 858 |
EBITDA margin
-3.1%
This company
15.8%
Market median
-120% vs market
20202024
Equity ratio
83.3%
This company
38.2%
Market median
+118% vs market
20202024
Return on equity
-6.2%
This company
18.4%
Market median
-134% vs market
20202024
Net profit margin
-9.4%
This company
8.1%
Market median
-216% vs market
20202024
Asset turnover
0.55×
This company
1.12×
Market median
-51% vs market
20202024
Debt / equity
0.20×
This company
0.62×
Market median
+68% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JN Chief Executive Officer | Chief Executive Officer | 2020 |
| Former (6) | ||
SK Confidential Clerk | Confidential Clerk | 2013 – 2021 |
SS | Audit | 2020 – 2022 |
PI Deputy Member | Deputy Member | 2020 – 2023 |
MM Chief Executive Officer | Chief Executive Officer | 2013 – 2020 |
JK Audit | Audit | 2012 – 2020 |
JP | Audit | 2022 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2023 | |
| Board of Directors | 2023 | |
| Former (8) | ||
| Chairperson | 2017 – 2019 | |
| Board of Directors | 2017 – 2020 | |
| Board of Directors | 2017 – 2020 | |
| Board of Directors | 2017 – 2020 | |
| Board of Directors | 2020 – 2020 | |
| Board of Directors | 2017 – 2019 | |
| Board of Directors | 2017 – 2020 | |
| Board of Directors | 2017 – 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 84.7% | 84.7% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Labquality Oy (this company)
Clinical Consulting Sp. z.o.o.Scandinavian CRO ABLabquality Polska Sp. z o.o.ARTIMED Medical Consulting GmbHQadvis Holdco ABP.R.I.S.M.A.-CRO Clinical Research Organisation GmbHBoard members of Labquality Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sirpa Kyllikki Hannula | Confidential Clerk | 0 companies |
| Sami Seppo Sakari Posti | Audit | 0 companies |
| Juha-Pekka Nuutinen | Chief Executive Officer | 0 companies |
| Pentti Ilari Kerola | Deputy Member | 0 companies |
| Mia Maria Lindström | Chief Executive Officer | 0 companies |
| Janne Kari Ilari Elo | Audit | 0 companies |
| Jari Petteri Karppinen | Audit | 0 companies |
| Jouni Aaro Tapio Peltomaa | Chairperson | 0 companies |
| Maija Leena Lappalainen | Board of Directors | 0 companies |
| Kari Arvo Varkila | Board of Directors | 0 companies |
| Leila Annikki Muukkonen | Board of Directors | 0 companies |
| Jaana Elina Grüter | Board of Directors | 0 companies |
| Olli Pekka Karhi | Board of Directors | 0 companies |
| Tarja Irmeli Myllärinen | Board of Directors | 0 companies |
| Theodor Mark Wuppermann | Board of Directors | 0 companies |
| Jaana Maarit Susanna Mättö | Board of Directors | 0 companies |
| Anna-Maria Linko-Parvinen | Board of Directors | 0 companies |